EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy

J Wynn, S Rego, D Chandler-Brown, R Carter, A Talati, M Zaretsky, A Trimble

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2025.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von J Wynn und 6 weiteren Autor:innen. Beteiligte Einrichtung: BillionToOne Inc., Menlo Park, CA, USA. Electronic address: jwynn@billiontoone.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cell-Free Nucleic Acids, Noninvasive Prenatal Testing, Fetal Therapies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent improvements in cell-free DNA technology have enabled non-invasive prenatal testing (NIPT) to screen for fetal single-gene autosomal recessive conditions from maternal blood as early as the first trimester. This technique can determine the fetal risk for cystic fibrosis (CF) with a single blood sample from a pregnant person without the need for a partner sample, which is required for traditional carrier screening. A retrospective review of 100,106 consecutive general-risk pregnant patients who underwent CF carrier screening was completed. All positive CF carriers underwent cell-free DNA testing, which reported a risk of the fetus being affected with CF. Pregnancies with at least a 1 in 4 risk were classified as high risk. Results of confirmatory testing were solicited from all high-risk cases, and a random sample of 50 % of low-risk cases were used to compute test performance analytics. The study cohort included 2,587 CF carriers and 20 cases with high-risk cell-free DNA results where the CF-affected status of the fetus/neonate was known, of which 13 were affected. All cases (n = 8) with a 9 in 10 cell-free DNA estimated risk were affected. The assay correctly identified all known affected fetuses as high risk (sensitivity of 100 %). Of the 13 affected, 12 cases had at least one CFTR variant eligible for CFTR modulator therapy. Additionally, 75 % of all cell-free DNA fetal risk results were returned before 18.5 weeks gestation, providing ample time for diagnostic testing and initiation of in utero treatment if indicated. Carrier screening with reflex to cell-free DNA analysis provides a personalized fetal risk assessment and efficient turnaround times at an early gestational age, without the need for a partner sample for a general risk population. This screening method can precisely guide prenatal diagnostic testing to identify CF-affected fetuses that may benefit from in utero therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCell-Free Nucleic AcidsNoninvasive Prenatal TestingFetal TherapiesPrenatal DiagnosisHumansFemalePregnancyRetrospective StudiesAdultCystic Fibrosis Transmembrane Conductance RegulatorGenetic TestingRisk Assessment

Stichwörter der Autor:innen

CFTR modulator therpayCell-free DNA testingIn utero diagnosisReproductive carrier screening

Substanzen

Cell-Free Nucleic AcidsCystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • BillionToOne Inc., Menlo Park, CA, USA. Electronic address: jwynn@billiontoone.com.
  • BillionToOne Inc., Menlo Park, CA, USA.
  • Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, CO, USA.
  • Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA.

Zitieren

APA

Wynn, J., Rego, S., Chandler-Brown, D., Carter, R., Talati, A., Zaretsky, M., & Trimble, A. (2025). Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.08.004

Vancouver

Wynn J, Rego S, Chandler-Brown D, Carter R, Talati A, Zaretsky M, et al. Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.08.004

BibTeX
@article{Wynn2025,
  author = {Wynn, J and Rego, S and Chandler-Brown, D and Carter, R and Talati, A and Zaretsky, M and Trimble, A},
  title = {Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2025.08.004}
}
Kostenlos starten →